Skip to main content

Advertisement

SpringerLink
Log in

FK506 conversion for intractable rejection of the liver allograft

  • Original Articles
  • Published:
Transplant International

Abstract

Twenty-seven liver transplant recipients with intractable, biopsy-proven, acute or chronic rejection (defined as vanishing bile duct syndrome) were conerted from cyclosporin to FK506. Successful conversion was achieved in 9 of 15 patients with acute rejection and in 6 of 12 patients with vanishing bile duct syndrome. A normal bilirubin was achieved more quickly in those with acute rejection (within 1 moth) than in those with chronic rejection (within 3 months). A preconversion total bilirubin of less than 12 mg/dl was considered significant with regard to a successful outcome (P=0.002). Graft survival was 66.7% and patient survival 73% in the case of acute rejection, and 50% and 66.7%, respectively, in the case of chronic rejection. Nephrotoxicity, neurotoxicity, and gastroitestinal side effects were the most serious complications of FK506 conversion. Six of ten patients had a drop in GFR that was 50% or greater a minimum of 1 month of FK506 exposure. The mean maintenance dose of FK506 to maintain FK506 serum levels of 0.5–1.5 ng/ml was 0.07 mg/kg per 12 h for adults (half the recommended dose), compared to 0.15 mg/kg per 12 h for pediatric patients. This study demonstrates that FK506 can be used successfully to convert patients with intractable acute and chronic rejection. Careful adjustments of FK506 dosages and levels are required to minimize side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, Takaya S, Todo S, Shannon WD, Starzl TE (1991) The effect of graft function on FK506 plasma levels, dosages, and renal function with particular reference to the liver. Transplantation 52: 71–77

    Google Scholar 

  2. Busuttil RW, Colonna JO, Hiatt JR, Brems JJ, ElKhoury G, Goldstein LI, Quinones-Baldrich WJ, Abdul-Rasool IH, Ramming KP (1987) The first 100 liver transplants at UCLA. Ann Surg 206: 387–402

    Google Scholar 

  3. Calne R, Collier DSJ, Thiru S (1987) Orthotopicliver transplantation in dogs receiving FK506. Transplant Proc 19 [Suppl 6]:63–67

    Google Scholar 

  4. Christians U, Braun F, Kosian N, Schmidt M, Schiebel H, Ernst L, Kruse C, Winkler M, Holze I, Linck A, Sewing K (1991) High performance liquid chromatography/mass spectometry of FK506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 23: 2741–2744

    Google Scholar 

  5. D'Alessandro AM, Kalayoglu M, Pirsch JD, Corwith C, Knechtle SJ, Reed A, Belzer FO (1991) FK506 rescue therapy for resistant rejection episodes in liver transplant recipients. Transplant Proc 23: 2987–2988

    Google Scholar 

  6. Demetris AJ, Fung JJ, Todo S, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE (1992) Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 53: 1056–1062

    Google Scholar 

  7. Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE (1990) Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 22: 6–12

    Google Scholar 

  8. Harding MW, Galat A, Uehling DE, Schreiber SL (1989) A receptor for the immunosuppressant FK506 is a cis-trans peptidylprolyl isomerase. Nature 341: 758

    Google Scholar 

  9. Hubscher SG, Buckels JAC, Elias E, McMaster P, Neuberger J (1991) Vanishing bile-duct syndrome following liver transplantation — is it reversible? Transplantation 51: 1004–1010

    Google Scholar 

  10. Jain AB, Fung JJ, Venkataramanan R, Todo S, Alessiani M, Starzl TE (1990) FK506 dosage in human organ transplantation. Transplant Proc 22: 23–24

    Google Scholar 

  11. Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, Starzl TE (1990) Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 22: 57–59

    Google Scholar 

  12. Jain A, Fung J, Venkataramanan R, Tzakis A, Abu-Elmagd K, Alessiani M, Todo S, Reyes J, Irish W, Warty V, Mehta S, Todo S, Starzl TE (1991) Comparative study of cyclosporine and FK506 dosage requirement in adult and pediatric orthotopic liver transplantation. Transplant Proc 23: 2763–2766

    Google Scholar 

  13. Johansson A, Möller E (1990) Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. Transplantation 50: 1001–1007

    Google Scholar 

  14. Jusko W, D'Ambrosio R (1991) Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 23: 2732–2735

    Google Scholar 

  15. Kino T, Hatanaka H, Kohsaka M, Aoki H, Ochiai T (1987) FK506, a novel immunosuppressant isolated from a streptomces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot 40: 1256–1265

    Google Scholar 

  16. Lewis WD, Jenkins RL, Burke PA, Winn KM, Shaffer D, Lopez R, Monaco AP (1991) FK506 rescue therapy in liver tranplant recipients with drug-resistant rejection. Transplant Proc 23: 2989–2991

    Google Scholar 

  17. McCauley J, Fung J, Jain A, Todo S, Starzl TE (1990) The effects of FK506 on renal function after liver transplantation. Transplant Proc 22: 17–20

    Google Scholar 

  18. McDiarmid SV, Colonna J, Shaked A, Ament M, Busuttil R (1992) A comparison of renal function in cyclosporine (CsA) and FK506 treated patients after primary orthotopic liver transplantation (OLT) (abstract). XIV International Congress of the Transplantation Society, Paris

  19. Mieles L, Todo S, Fung JJ, Jain A, Furukawa H, Susuki M, Starzl TE (1990) Oral glucose tolerance test in liver recepients treated with FK506. Transplant Proc 22: 41–43

    Google Scholar 

  20. Mor E, Solomon H, Gibbs JF, Holman MJ, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB (1992) Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome. Semin Liver Dis 12: 28–40

    Google Scholar 

  21. Reding R, Ville de Goyet J de, Sokal E, Moulin D, Clement de Clety S, Wallemacq P, Otte JB (1991) Compassionate use of FK506 in pediatric liver transplantation: a pilot study. Transplant Proc 23: 3002–3004

    Google Scholar 

  22. Rucay P, Samuel D, Gillet D, Bismuth H (1992) FK506 rescue therapy for refractory acute rejection in five liver recipients. Transplant Proc 23: 3000–3001

    Google Scholar 

  23. Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251: 283–287

    Google Scholar 

  24. Scott JP, Higenbottam T (1988) Adverse reactions and interactions of cyclosporine. Me Toxicol 13: 107–127

    Google Scholar 

  25. Shapriro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE (1990) The side effects of FK506 in humans. Transplant Proc 22: 35–36

    Google Scholar 

  26. Shaw BW, Markin R, Stratta R, Donovan J, Sorrell M (1991) FK506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc 23: 2994–2995

    Google Scholar 

  27. Siekierka JJ, Hung SHY, Poe M, Lin CS, Sigal NH (1989) A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341: 755–757

    Google Scholar 

  28. Starzl TE, Schneck SA, Mazzoni G, Aldrete JA, Porter KA, Schroter GPJ, Koep LJ, Putnam CW (1978) Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus. Ann Surg 187: 236–240

    Google Scholar 

  29. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A (1989) FK506 for human liver, kidney, and pancreas transplantation. Lancet II: 1000–1004

    Google Scholar 

  30. Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, Kaizu T, Tanaka H, Niwa M (1982) A highly sensitive method to assay FK 506 levels in plasma. Transplant Proc 19: 23–29

    Google Scholar 

  31. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143: 718–726

    Google Scholar 

  32. Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanan R, Makowka L, Starzl TE (1988) Immunosuppression of canine, monkey, and baboon allografts by FK506: with special reference to synergism with other drugs and to tolerance induction. Surgery 104: 239–249

    Google Scholar 

  33. Todo S, Fung JJ, Demetris AJ, Jain A, Venkatarmanan R, Starzl TE (1990) Early trials with FK506 as primary treatment in liver transplantation. Transplant Proc 22: 13–16

    Google Scholar 

  34. Winkler M, Ringe B, Gerstenkorn C, Rodeck B, Gubernatis G, Wonigeit K, Pichlmayr R (1991) Use of FK506 for treatment of chronic rejection after liver transplantation. Transplant Proc 23: 2984–2986

    Google Scholar 

  35. Woodle ES, Perdrizet GA, Brunt EM, Brunt EM, So SKS, Jendrisak MD, McCullough CS, Vehe KL, White HM, Peters MG, Marsh JW (1991) FK506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. Transplant Proc 23: 2992–2993

    Google Scholar 

  36. Zeevi A, Eiras G, Burckart G, Jain A, Kragack A, Venkataramanan R, Todo S, Fung J, Starzl TE, Duquesnoy RJ (1990) Bioassay of plasma specimens from liver transplant patients on FK506 immunosuppression. Transplant Proc 22: 60–63

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of California at Los Angeles Medical Center, MDCC 12-383, 90024-1752, Los Angeles, CA, USA

    Sue V. McDiarmid

  2. Transplantation Services, Department of Surgery, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX, USA

    Goran B. Klintmalm

  3. Liver Transplant Program, Department of Surgery, University of California at Los Angeles Medical Center, 10833 Le Conte Avenue, 90024, Los Angeles, CA, USA

    Ronald W. Busuttil

Authors
  1. Sue V. McDiarmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Goran B. Klintmalm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald W. Busuttil
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

McDiarmid, S.V., Klintmalm, G.B. & Busuttil, R.W. FK506 conversion for intractable rejection of the liver allograft. Transplant Int 6, 305–312 (1993). https://doi.org/10.1007/BF00335966

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00335966

Key words

Search

Navigation